Big cardio is back in focus

Last fall at ESC it became apparent that big cardio diseases are back in vogue. Merck’s picked up on this by making cardio a top growth sector in the pipeline. And we’ve been seeing a surge in new R&D projects. All this after big costs and low success rates forced a rethink in Big Pharma. What’s happening now to inspire such a big change? Lei Lei Wu is digging in.

First name

Last name

Company

Job Title

Country

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct communication from the sponsor(s).

If you are experiencing problems with your registration, please try the Zoom registration page.

Sameer Bansilal

Vice President U.S. Medical Affairs, Cardiovascular, Bayer

David Soergel

Global Head, Cardiovascular, Renal and Metabolism Development Unit, Novartis

Moderator

Lei Lei Wu

NEWS REPORTER, Endpoints News

Lei Lei (pronounced "Lay Lay") joined Endpoints as a news reporter in 2022. She graduated from Cornell University, where she studied biochemistry and had a column in the student paper. She splits her time between New York and New Jersey, and outside of work, you might find her concocting new coffee creations or binge-watching sci-fi shows.